| scholarly article | Q13442814 |
| P2093 | author name string | J-Y Reginster | |
| S T Harris | |||
| S L Silverman | |||
| C E Barr | |||
| C Harley | |||
| S A Poston | |||
| W A Blumentals | |||
| P433 | issue | 5 | |
| P921 | main subject | bone fracture | Q68833 |
| P304 | page(s) | 758-765 | |
| P577 | publication date | 2009-01-09 | |
| P1433 | published in | Bone | Q15755003 |
| P1476 | title | Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study | |
| P478 | volume | 44 |
| Q36059535 | Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis |
| Q50960935 | Bilateral distal fibula fractures in a woman on long-term bisphosphonate therapy. |
| Q34440107 | Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary |
| Q36311593 | Clinical role of bisphosphonate therapy |
| Q37862933 | Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates |
| Q54205972 | Combined use of ibandronate and eldecalcitol in postmenopausal Japanese women with osteoporosis. |
| Q37402282 | Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. |
| Q46059124 | Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. |
| Q37843715 | Current and future treatment options in osteoporosis |
| Q44574043 | Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy |
| Q33965657 | Efficacy of ibandronate: a long term confirmation. |
| Q36056975 | Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review |
| Q34099162 | Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club |
| Q42108489 | Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control |
| Q37388453 | Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment. |
| Q42877288 | Health-related quality of life among patients with postmenopausal osteoporosis treated with weekly and monthly bisphosphonates. |
| Q53559191 | Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study. |
| Q38750001 | Ibandronate: A Review in Japanese Patients with Osteoporosis |
| Q37973239 | Individualizing osteoporosis therapy |
| Q34758140 | Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis |
| Q44468289 | Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies |
| Q33819111 | Longitudinal change in clinical fracture incidence after initiation of bisphosphonates |
| Q44381104 | Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study |
| Q51140318 | Medication use before and after hip fracture: a population-based cohort and case-control study. |
| Q91671758 | Monthly minodronate inhibits bone resorption to a greater extent than does monthly risedronate |
| Q48581497 | Monthly or weekly bisphosphonate? Evaluation of satisfaction in patients with postmenopausal osteoporosis using OPSAT-Q questionnaire during the BOOSTER study in Croatia. |
| Q46244082 | Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice |
| Q34242906 | Osteoporosis therapies: evidence from health-care databases and observational population studies |
| Q38104738 | Osteoporosis treatment: why ibandronic acid? |
Search more.